证券简称：星云股份 证券代码：300648 | 投资者关系活动类别 | | 特定对象调研 分析师会议 | 媒体采访 | | --- | --- | --- | --- | | | 业绩说明会 □路演活动 | □新闻发布会 | | | | □现场参观 其他 | | | | 参与单位名称 | 国盛证券、太平基金、德邦基金、国泰基金、宏道投资、 | | | | 及人员姓名 | 广州雪球投资 | | | | 时间 | 2025年6月19日14:00-16:00 | | | | 地点 | 福建省福州市马尾区马江路7号星云科技园公司会议室 | | | | 上市公司接待人员姓名 | 董事、副总经理、董事会秘书：许龙飞 | | | | | 投资者关系总监：吴荣 | | | | | 1.当前公司业务基本情况如何展望？ | | | | | 答：2025 年第一季度营业收入同比实现增长，利润同比 | | | | | 改善，当前下游客户景气度有所复苏，出海节奏加快，有 | | | | | 望带来行业情况改善。 | | | | | 2.《电动汽车用动力蓄电池安全要求》新规对公司业务有 | | | | | 何影响？ | | | ...

Company Overview - Vizian serves 97% of academic medical centers in the US, over 69% of acute care hospitals, and more than 35% of the ambulatory market [1] - Vizian is developing a generative AI platform to improve healthcare providers' data access and analysis [2] Challenges Before Langraph and Langsmith - Scaling LLM queries using Azure OpenAI faced token limit issues, impacting performance [3] - Limited visibility into system performance made it difficult to track token usage, prompt efficiency, and reliability [3] - Continuous testing was not feasible, leading to reactive problem-solving [4] - Multi-agent architecture introduced complexity, requiring better orchestration [4] - Lack of observability tools early on resulted in technical debt [4] Impact of Integrating Langraph and Langsmith - Gained the ability to accurately estimate token usage, enabling proper capacity provisioning in Azure OpenAI [5] - Real-time insights into system performance facilitated faster issue diagnosis and resolution [6] - Langraph provided structure and orchestration for multi-agent workflows [6] - Resolved LLM rate limiting issues by optimizing token usage and throughput allocation [7] - Development and debugging processes became significantly faster [8] - Shift to automated continuous testing dramatically improved system quality and reliability [8] - Rapidly turn beta user feedback into actionable improvements [8] Recommendations - Start with a slim proof of concept and model one high impact user flow in Langraph [9] - Integrate with Langsmith from day one and treat every run as a data point [9] - Define a handful of golden query response pairs upfront and use them for acceptance testing [9] - Budget a short weekly review of Langsmith's run history [9]

Carrying a Zacks Rank #3 (Hold) at present, the laboratory service provider is concentrating more on areas that represent major growth opportunities and are expected to grow significantly faster than other therapeutic areas. It maintains a solid pipeline of potential acquisitions that fit its financial strategy and will enhance its organic growth. Additionally, the success of the LaunchPad initiative and a solid financial footing are highly encouraging for the company. Based in Burlington, NC, Labcorp offer ...

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Managed Waste Service ("MWS"), a leading Australian waste management provider, plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and green waste processing sites. The decision marks MWS's fir ...

Okay, now let's talk about back testing and back testing. If I start over back testing, not sure what specific questions you have, but let me show you how to do back testing. And if I just uh go come to a screener, one of my pre-existing screeners like the high quality one, if I just select that one, the filter is set already here.uh it has financial strength requirement, profitability rank requirement, predictability and roe. If I do want to do back testing, I just click on back testing here and I select a ...

Showcasing Global Utility of its QAPs at Point-of-Care Testing Conference MISSISSAUGA, Ontario, June 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, announces that it is attending and presenting at the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases, taking place in Bangkok, Thailand from 19 to 21 June, 2025 ("POC 2025"). At POC 2025, Microbix will be presenting a poster of results a ...

The Company remains committed to its goal of delivering a clinically available molecular diagnostic kit to expand testing access for kidney transplant patients, which it anticipates will unlock value in the estimated $1 billion addressable market for transplant rejection testing. So far in 2025, iMDx believes it has made disciplined and focused progress toward this goal, executing the critical steps required to transition from product development to commercialization. To support these efforts, iMDx is reloc ...

Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace SafetyDALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug test ...

Company Overview - Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care [5] - The company's flagship offering, HealthTab™, aims to create the world's largest network of rapid testing devices in community pharmacies [5] Stock Options Announcement - The board of directors of Avricore has approved the granting of stock options for a total of 4,100,000 common shares at an exercise price of CAD $0.05 per share [1] - The options will vest quarterly starting from the date of grant and will expire 5 years from the grant date, contingent on the optionees remaining in their roles [2] HealthTab™ Product Details - HealthTab™ is a point-of-care testing solution that provides lab-accurate results from just a few drops of blood, with real-time data reporting [3] - The test menu includes up to 23 key biomarkers for chronic disease management, including diabetes and heart disease, and has recently added capabilities for bacterial and viral tests [3] HealthTab™ Network Model - The HealthTab™ network model enhances the role of pharmacists in primary care delivery and empowers patients to take control of their health [4] - It aims to reduce costs and waiting times while providing multiple revenue streams, including equipment leasing, direct access testing, and decentralized clinical trials [4]

Core Insights - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls, surpassing Regeneron Pharmaceuticals' previous offer of $256 million in a bankruptcy auction [1][2] - The deal is expected to close soon, pending a court hearing scheduled for June 17 [1] - 23andMe filed for bankruptcy in March due to declining demand and a data breach in 2023 that compromised sensitive customer information [2][6] Company Developments - 23andMe's bankruptcy filing was a result of a significant decline in consumer demand for DNA testing services [2][6] - The company faced legal challenges, with New York and over two dozen other states suing to contest the sale of its customers' private information [3] - TTAM Research Institute, associated with Wojcicki, has committed to upholding 23andMe's existing privacy policies and complying with data protection laws [2] Competitive Landscape - Regeneron Pharmaceuticals initially offered $256 million for 23andMe, which was later outbid by Wojcicki's nonprofit [1][5] - Regeneron expressed willingness to make a new bid but requested a $10 million breakup fee if Wojcicki's bid is accepted [5]